2 Xideas Ag Halozyme Therapeutics, Inc. Transaction History

2 Xideas Ag

$681 Million
Q3 2024

A detailed history of 2 Xideas Ag transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, 2 Xideas Ag holds 305,587 shares of HALO stock, worth $14.4 Million. This represents 2.57% of its overall portfolio holdings.

Number of Shares

305,587

Previous 498,957 38.75%

Holding current value

$14.4 Million

Previous $26.1 Million 33.08%

% of portfolio

2.57%

Previous 3.46%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$51.3 - $64.42 $9.92 Million - $12.5 Million	-193,370 Reduced 38.75%	305,587 $17.5 Million
Q2 2024 Aug 14, 2024	SELL	$37.81 - $52.4 $624,054 - $864,862	-16,505 Reduced 3.2%	498,957 $26.1 Million
Q1 2024 May 14, 2024	SELL	$33.68 - $41.95 $966,750 - $1.2 Million	-28,704 Reduced 5.27%	515,462 $21 Million
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $1.89 Million - $2.38 Million	-56,633 Reduced 9.43%	544,166 $20.1 Million
Q3 2023 Nov 07, 2023	SELL	$36.46 - $44.03 $1.62 Million - $1.96 Million	-44,489 Reduced 6.89%	600,799 $23 Million
Q2 2023 Aug 10, 2023	BUY	$30.28 - $38.74 $2.96 Million - $3.78 Million	97,669 Added 17.84%	645,288 $23.3 Million
Q1 2023 May 11, 2023	BUY	$32.86 - $55.7 $4.31 Million - $7.3 Million	131,033 Added 31.45%	547,619 $20.9 Million
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $7.62 Million - $11.3 Million	190,115 Added 83.95%	416,586 $23.7 Million
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $3.78 Million - $5.08 Million	-98,148 Reduced 30.23%	226,471 $8.96 Million
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $12.1 Million - $15.7 Million	324,619 New	324,619 $14.3 Million

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.54B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of 2 Xideas Ag, based on Form 13F filings with the SEC.

News

Stay updated on 2 Xideas Ag with notifications on news.

Account